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Introduction
3,5-Di-t-butyl catechol (DTCAT) has been shown to
release Ca2+ from rat skeletal muscle sarcoplasmic reticu-
lum (SR) vesicles, which makes it a possible candidate for
use as a substitute for halothane or caffeine in the in vitro
contracture test (IVCT) for the assessment of susceptibility
to malignant hyperthermia (MHS).
Methods
To characterize the effect of DTCAT at the cellular level,
Ca2+ release experiments were performed on cultured,
human skeletal muscle cells using the fluorescent Ca2+
indicator fura2-AM. DTCAT was also used for the first
time in the IVCT to induce contractures in human skeletal
muscle bundles obtained from individuals diagnosed sus-
ceptible (MHS), normal (MHN) or equivocal (MHE);
these effects were compared to those elicited by the stand-
ard test substances caffeine and halothane.
Results
In single cultured skeletal muscle cells, DTCAT released
Ca2+ from intracellular stores with a higher potency when
compared to caffeine. This effect, however, was unspecific,
since the release of Ca2+ from stores other than the SR was
evident, as well as a Ca2+ influx, possibly triggered by
depletion of intracellular Ca2+ stores. DTCAT induced
contractures in skeletal muscle bundles in a concentra-
tion-dependent manner with an EC50 value of 160 ± 91μM. However, the reaction to DTCAT in muscles from
MHS individuals was similar to reactions to DTCAT in
MHE or MHN muscles.
Conclusion
Due to its low specificity in inducing the release of Ca2+
from SR stores and the additional activation of Ca2+
influx, DTCAT is not an appropriate test substance for the
diagnosis of MH.
from 15th Scientific Symposium of the Austrian Pharmacological Society (APHAR) Joint meeting with the Hungarian Society of Experimental and Clinical 
Pharmacology (MFT) and the Slovenian Pharmacological Society (SDF)
Graz, Austria. 19-21 November 2009
Published: 12 November 2009
BMC Pharmacology 2009, 9(Suppl 2):A22 doi:10.1186/1471-2210-9-S2-A22
<supplement> <title> <p>15th Scientific Symposium of the Austrian Pharmacological Society (APHAR)</p> </title> <editor>Andrea Laslop and Thomas Griesbacher</editor> <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2210-9-S2-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2210-9-S2-info.pdf</url> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/9/S2/A22
© 2009 Lacava et al; licensee BioMed Central Ltd. 
